{"success":true,"data":{"pressRelease":{"id":"17612","rtpr_id":"nGNX5J2mqk","ticker":"NAMSW","exchange":"NASDAQ","all_tickers":["NAMSW","KH6"],"title":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-05-01T20:57:13.099Z","article_body":"NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) --\nNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the\n“Company”), a late-stage, clinical biopharmaceutical company developing\noral, non-statin medicines for patients at risk of cardiovascular disease\n(“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”),\nfor whom existing therapies are not sufficiently effective or well-tolerated,\ntoday announced that the Compensation Committee of NewAmsterdam’s Board of\nDirectors approved the grant of inducement share options covering an aggregate\nof 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires.\nThe share options were granted as an inducement material to the employees’\nacceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma\nCompany N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in\naccordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe share options have an exercise price per share equal to $28.43, which\nrepresents the closing market price on the Nasdaq Stock Market of the\nCompany’s ordinary shares on May 1, 2026, the grant date. The shares subject\nto the options will vest over four years, with 25% of the shares vesting on\nthe one-year anniversary of the applicable vesting commencement date and the\nbalance of the shares vesting in a series of 36 equal monthly installments\nthereafter, subject to each employee’s continued service with NewAmsterdam\non such vesting dates. The options are subject to the terms and conditions of\nthe 2024 Inducement Plan and the terms and conditions of an option award\nagreement covering the grant.\n\nThe Compensation Committee of NewAmsterdam’s Board of Directors also\napproved the grant of restricted stock units covering an aggregate of 15,400\nof NewAmsterdam’s ordinary shares to five non-executive new hires. The\nrestricted stock units were granted as an inducement material to the\nemployees’ acceptance of employment with NewAmsterdam pursuant to the 2024\nInducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe restricted stock units were granted on May 1, 2026. The restricted stock\nunits will vest over three years, with one-third of the restricted stock units\nvesting on each of the one-year, two-year and three-year anniversaries of the\napplicable vesting commencement date, subject to each employee’s continued\nservice with NewAmsterdam on such vesting dates. The restricted stock units\nare subject to the terms and conditions of the 2024 Inducement Plan and the\nterms and conditions of a restricted stock unit award agreement covering the\ngrant.\n\nAbout NewAmsterdam\nNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company\nwhose mission is to improve patient care in populations with metabolic\ndiseases where currently approved therapies have not been adequate or well\ntolerated. We seek to fill a significant unmet need for a safe, well-tolerated\nand convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam\nis investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor,\nalone or as a fixed-dose combination with ezetimibe, as LDL-C lowering\ntherapies to be used as an adjunct to statin therapy for patients at risk of\nCVD with elevated LDL-C, for whom existing therapies are not sufficiently\neffective or well tolerated.\n\nCompany Contact\nMatthew Philippe\nP: 1-917-882-7512\nmatthew.philippe@newamsterdampharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f7b8b881-9461-4712-9965-707ed3bdd573)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5J2mqk","title":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"NAMSW","created":"2026-05-01T20:57:13.099Z","tickers":["NAMSW","KH6"],"exchange":"NASDAQ","article_body":"NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) --\nNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the\n“Company”), a late-stage, clinical biopharmaceutical company developing\noral, non-statin medicines for patients at risk of cardiovascular disease\n(“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”),\nfor whom existing therapies are not sufficiently effective or well-tolerated,\ntoday announced that the Compensation Committee of NewAmsterdam’s Board of\nDirectors approved the grant of inducement share options covering an aggregate\nof 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires.\nThe share options were granted as an inducement material to the employees’\nacceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma\nCompany N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in\naccordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe share options have an exercise price per share equal to $28.43, which\nrepresents the closing market price on the Nasdaq Stock Market of the\nCompany’s ordinary shares on May 1, 2026, the grant date. The shares subject\nto the options will vest over four years, with 25% of the shares vesting on\nthe one-year anniversary of the applicable vesting commencement date and the\nbalance of the shares vesting in a series of 36 equal monthly installments\nthereafter, subject to each employee’s continued service with NewAmsterdam\non such vesting dates. The options are subject to the terms and conditions of\nthe 2024 Inducement Plan and the terms and conditions of an option award\nagreement covering the grant.\n\nThe Compensation Committee of NewAmsterdam’s Board of Directors also\napproved the grant of restricted stock units covering an aggregate of 15,400\nof NewAmsterdam’s ordinary shares to five non-executive new hires. The\nrestricted stock units were granted as an inducement material to the\nemployees’ acceptance of employment with NewAmsterdam pursuant to the 2024\nInducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe restricted stock units were granted on May 1, 2026. The restricted stock\nunits will vest over three years, with one-third of the restricted stock units\nvesting on each of the one-year, two-year and three-year anniversaries of the\napplicable vesting commencement date, subject to each employee’s continued\nservice with NewAmsterdam on such vesting dates. The restricted stock units\nare subject to the terms and conditions of the 2024 Inducement Plan and the\nterms and conditions of a restricted stock unit award agreement covering the\ngrant.\n\nAbout NewAmsterdam\nNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company\nwhose mission is to improve patient care in populations with metabolic\ndiseases where currently approved therapies have not been adequate or well\ntolerated. We seek to fill a significant unmet need for a safe, well-tolerated\nand convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam\nis investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor,\nalone or as a fixed-dose combination with ezetimibe, as LDL-C lowering\ntherapies to be used as an adjunct to statin therapy for patients at risk of\nCVD with elevated LDL-C, for whom existing therapies are not sufficiently\neffective or well tolerated.\n\nCompany Contact\nMatthew Philippe\nP: 1-917-882-7512\nmatthew.philippe@newamsterdampharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f7b8b881-9461-4712-9965-707ed3bdd573)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-01T20:57:13.138032576Z","server_sent_at_ms":1777669033138},"received_at":"2026-05-01T20:57:13.189Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}